Who are Double-blind adalimumab's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Adalimumab and its biosimilars, Adalimumab Ab, Akkermansia muciniphila + Infliximab, Golimumab treatment optimization., Biosimilar Infliximab, Adalimumab treatment arm.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/double-blind-adalimumab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Double-blind adalimumab — Competitive Intelligence Brief

Double-blind adalimumab (Double-blind adalimumab) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: TNF-α inhibitor. Area: Immunology.

phase 3 TNF-α inhibitor TNF-α (tumor necrosis factor-alpha) Immunology Biologic Live · refreshed every 30 min

Target snapshot

Double-blind adalimumab (Double-blind adalimumab) — Abbott. Adalimumab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Double-blind adalimumab TARGET	Double-blind adalimumab	Abbott	phase 3	TNF-α inhibitor	TNF-α (tumor necrosis factor-alpha)
Adalimumab and its biosimilars	Adalimumab and its biosimilars	Hanyang University Seoul Hospital	marketed	TNF-α inhibitor (monoclonal antibody)	TNF-α (tumor necrosis factor-alpha)
Adalimumab Ab	Adalimumab Ab	Qilu Hospital of Shandong University	marketed	TNF-α inhibitor (monoclonal antibody)	TNF-α (Tumor Necrosis Factor-alpha)
Akkermansia muciniphila + Infliximab	Akkermansia muciniphila + Infliximab	Chinese Medical Association	marketed	Combination therapy: probiotic + TNF-α inhibitor	TNF-α (infliximab component); gut microbiota modulation (Akkermansia muciniphila component)
Golimumab treatment optimization.	Golimumab treatment optimization.	Hospital de Manises	marketed	TNF-α inhibitor (monoclonal antibody)	TNF-α (Tumor Necrosis Factor-alpha)
Biosimilar Infliximab	Biosimilar Infliximab	Hikma Pharmaceuticals LLC	marketed	TNF-α inhibitor (monoclonal antibody)	TNF-α (tumor necrosis factor-alpha)
Adalimumab treatment arm	Adalimumab treatment arm	Medical University of Vienna	marketed	TNF-α inhibitor (monoclonal antibody)	TNF-α (tumor necrosis factor-alpha)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (TNF-α inhibitor class)

Abbott · 1 drug in this class
Alvotech Swiss AG · 1 drug in this class
Astellas Pharma Inc · 1 drug in this class
Innovaderm Research Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Double-blind adalimumab — Competitive Intelligence Brief. https://druglandscape.com/ci/double-blind-adalimumab. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab